Evidence map›Paper›PMID 39430578›Full record

ArticleJHEP reports : innovation in hepatology2024

Altered fatty acid metabolism rewires cholangiocarcinoma stemness features.

Giulia Lori, Mirella Pastore, Nadia Navari, Benedetta Piombanti, Richell Booijink, Elisabetta Rovida, Ignazia Tusa, Monika Lewinska, Jesper B Andersen, Tiziano Lottini and 19 more

Abstract read
In one paragraph

Article in JHEP reports : innovation in hepatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. PHGDH drives 5-FU chemoresistance in colorectal cancer through the Hedgehog signaling.Journal of experimental & clinical cancer research : CR · 2025
    Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Giulia LoriDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Mirella PastoreDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Nadia NavariDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Benedetta PiombantiDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Richell BooijinkDepartment of Biomaterial Science and Technology, University of Twente Enschede, The Netherlands.
Elisabetta RovidaDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.
Ignazia TusaDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.
Monika LewinskaBiotech Research and Innovation Centre, Department of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Jesper B AndersenBiotech Research and Innovation Centre, Department of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Tiziano LottiniDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Annarosa ArcangeliDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Maria Letizia TaddeiDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Erica PranziniDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.
Caterina ManciniDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Cecilia AnceschiDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.
Stefania MadiaiDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Elena SaccoDepartment of Biotechnology and Biosciences, University of Milano-Bicocca, Milan, Italy.
Stefano RotaDepartment of Biotechnology and Biosciences, University of Milano-Bicocca, Milan, Italy.
Adriana TrapaniDepartment of Pharmacy-Drug Sciences, University of Bari, Bari, Italy.
Gennaro AgrimiDepartment of Biosciences, Biotechnologies and Environment, University of Bari, Bari, Italy.
Matteo RamazzottiDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.
Paola OstanoCancer Genomics Lab, Fondazione Edo ed Elvo Tempia, Biella, Italy.
Caterina Peraldo NeiaCancer Genomics Lab, Fondazione Edo ed Elvo Tempia, Biella, Italy.
Matteo ParriDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.
Fabrizia CarliInstitute of Clinical Physiology, National Research Council, CNR, Pisa, Italy.
Silvia SabatiniInstitute of Clinical Physiology, National Research Council, CNR, Pisa, Italy.
Amalia GastaldelliInstitute of Clinical Physiology, National Research Council, CNR, Pisa, Italy.
Fabio MarraDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Chiara RaggiDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background & Aims: Among the reprogrammed metabolic pathways described in cancer stem cells, aberrant lipid metabolism has recently drawn increasing attention. Our study explored the contribution of fatty acids (FA) in the regulation of stem-like features in intrahepatic cholangiocarcinoma (iCCA). Methods: We previously identified a functional stem-like subset in human iCCA by using a three-dimensional sphere (SPH) model in comparison to parental cells grown as monolayers (MON). In this study, quantification of intracellular free FA and lipidomic analysis (triacylglycerol [TAG] composition, Results: Stem-like SPH showed a superior content of free FA (citric, palmitic, stearic, and oleic acids) and unsaturated TAG. Molecularly, SPH showed upregulation of key metabolic enzymes involved in Conclusion: Altered FA metabolism contributes to the maintenance of a stem-like phenotype in iCCA. FASN inhibition may represent a new approach to interfere with the progression of this deadly disease. Impact and implications: Recent evidence indicates that metabolic disorders correlate with an increased susceptibility to intrahepatic cholangiocarcinoma (iCCA). Our investigation emphasises the pivotal involvement of lipid metabolism in the tumour stem cell biology of iCCA, facilitated by the upregulation of crucial enzymes and the mTOR signalling pathway. From a clinical perspective, this underscores the dual role of FASN as both a prognostic indicator and a therapeutic target, suggesting that FASN inhibitors could enhance patient outcomes by diminishing stemness and tumour aggressiveness. These findings pave the way for novel therapeutic strategies for iCCA and shed light on its relationship with metabolic disorders such as diabetes, obesity, metabolic syndrome, and metabolic dysfunction-associated steatotic liver disease.

Indexed as

Cancer stem cellsHepatobiliary tumoursLipid dropletsLipid metabolismOleic acidPalmitoleic acidtriglycerides

Identifiers

PMID39430578
PMCPMC11486925

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.